The long-acting
glucagon-like peptide-1 receptor (GLP1R) agonist,
semaglutide and the unimolecular
glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP1R dual-agonist,
tirzepatide have been successfully introduced as therapeutic options for patients with Type-2 diabetes (T2DM) and
obesity.
Proglucagon-derived
peptides from phylogenetically ancient fish act as naturally occurring dual agonists at the GLP1R and the
glucagon receptor (GCGR) with lamprey
GLP-1 and paddlefish
glucagon being the most potent and effective in stimulating
insulin release from BRIN-BD11 clonal β-cells. These
peptides were also the most effective in lowering
blood glucose and elevating plasma
insulin concentrations when administered intraperitoneally to overnight-fasted mice together with a
glucose load. Zebrafish GIP acts as a dual agonist at the GIPR and GLP1R receptors. Studies with the high fat-fed mouse, an animal model with
obesity,
impaired glucose-tolerance and
insulin-resistance, have shown that twice-daily administration of the long-acting analogs [D-Ala2]palmitoyl-lamprey
GLP-1 and [D-Ser2]palmitoyl-paddlefish
glucagon over 21 days improves
glucose tolerance and
insulin sensitivity. This was associated with β-cell proliferation, protection of β-cells against apoptosis, decreased pancreatic
glucagon content, improved
lipid profile, reduced food intake and selective alteration in the expression of genes involved in β-cell stimulus-secretion coupling. In
insulin-deficient GluCreERT2;ROSA26-eYFP transgenic mice, the
peptides promoted an increase in β-cell mass with positive effects on transdifferentiation of
glucagon-producing to
insulin-producing cells. Naturally occurring fish dual agonist
peptides, particularly lamprey
GLP-1 and paddlefish
glucagon, provide templates for development into therapeutic agents for
obesity-related T2DM.